Pharmaceutical companies are committing massive capital to domestic manufacturing. This $3.5 billion Eli Lilly investment is just the beginning of a broader reshoring trend that could reshape the industry.
After years of overseas reliance, pharma giants are building fortress-like domestic operations. Companies supporting this infrastructure shift stand to benefit from sustained investment cycles.
Breakthrough treatments like obesity drugs are driving unprecedented demand. The race to scale production domestically creates opportunities across the entire pharmaceutical ecosystem.
Total market capitalisation is reported as $.000, with no constituent breakdown provided. Because no constituents are listed, dominance by large‑cap stocks cannot be confirmed.
Eli Lilly's massive $3.5 billion investment in U.S. manufacturing signals a broader pharmaceutical reshoring trend. As companies move production back home to create more resilient supply chains, an entire ecosystem of supporting businesses stands to benefit from this multi-billion pound shift.
This group combines established pharmaceutical giants with the specialised companies that make domestic manufacturing possible. From life sciences real estate to advanced equipment manufacturers, these businesses form the backbone of America's growing pharmaceutical independence.
Each company was handpicked by professional analysts for its strategic role in the pharmaceutical reshoring movement. Whether they're the drug makers themselves or the critical infrastructure providers, all are positioned to benefit from the substantial capital flowing into domestic bio-manufacturing.
Eli Lilly is investing $3.5 billion in a new U.S. plant to boost production of its popular obesity drugs. This move signals a broader trend of pharmaceutical reshoring, creating opportunities for companies that support and build out the domestic life sciences manufacturing infrastructure.
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Published on February 2
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Here are a few of the assets in this group. Create an account to unlock the full list.
WEST PHARMACEUTICAL SERVICES INC
WST
Current Price
$363.64
The company produces critical containment and delivery systems for injectable drugs, a foundational component for domestic pharmaceutical manufacturin...
The company produces critical containment and delivery systems for injectable drugs, a foundational component for domestic pharmaceutical manufacturing.
Join Nemo FREE today and unlock every stock
It only takes 60 seconds.
On average, analysts expect assets in this group to grow 9.42% over the next year.
1 of 1 assets in this group are rated Buy by professional analysts.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+9.42%
